08:26 AM EST, 02/26/2025 (MT Newswires) -- NewAmsterdam Pharma ( NAMS ) reported Wednesday that its full-year 2024 net loss widened to $241.6 million from a net loss of $176.9 million a year earlier.

Analysts polled by FactSet expected a loss of $194.5 million.

Revenue for full-year 2024 was $45.6 million up from $14.1 million a year earlier.

Analysts surveyed by FactSet expected $33.8 million.